Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 4/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080431 | 1.00 | CNR1 (0.42) | CNR1CNR2MAPK8STSPTPN2 | |
| SCHEMBL3072601 | 0.84 | CNR1 (0.42) | CNR1CNR2STSPTPN2PTPN1 | |
| SCHEMBL3072600 | 0.84 | CNR1 (0.42) | CNR1CNR2STSPTPN2PTPN1 | |
| SCHEMBL6220469 | 0.82 | CNR1 (0.45) | CNR1CNR2STSPTPN2PTPN1 | |
| SCHEMBL6216273 | 0.82 | CNR1 (0.42) | CNR1CNR2STSPTPN2PTPN1 | |
| SCHEMBL6668708 | 0.82 | CNR1 (0.41) | CNR1CNR2STSPTPN2PTPN1 | |
| SCHEMBL5848881 | 0.78 | GPR119 (0.40) | CNR1CNR2MAPK8STSUSP30 | |
| SCHEMBL5847234 | 0.77 | CNR1 (0.41) | CNR1CNR2STSUSP30PAK1 | |
| SCHEMBL6670108 | 0.77 | CNR1 (0.39) | CNR1CNR2STSUSP30PAK1 | |
| SCHEMBL6216941 | 0.77 | CNR1 (0.39) | CNR1CNR2STSUSP30PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795436-B2 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-14 | — | — | US | disclosed |
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | HTR2B, HTR2C, HTR1A | CNR1 21/4885CNR2 25/4885MAPK8 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.